Replies to post #30403 on Inovio Pharmaceuticals Inc (INO)

[Stockman1010101]

Analysts like INOVIO:

A Benchmark Research analyst expects that the Food and Drug Administration will allow Inovio Pharmaceuticals Inc.'s INO, -14.38% COVID-19 vaccine candidate to move to a Phase 2/3 study. Benchmark's Aydin Huseynov noted that while the Phase 1 efficacy data provided by Inovio before the market opened on Tuesday morning was "insufficient to make a judgment call about the future utility of the vaccine," he is still encouraged by the news. He reiterated a buy rating. The company's stock was down 23.7% in trading on Tuesday. Since the start of the year, Inovio's stock has soared 628.3%, while the S&P 500 SPX, +1.09% is down 5.5%.